Candesartan cilexetil - paediatric investigation plan

Candesartan cilexetil

Key facts

• Invented name:
  Blopress and associated names
• Active Substance:
  Candesartan cilexetil
• Therapeutic area:
  Cardiovascular diseases
• Decision number:
  P/22/2009
• PIP number:
  Candesartan cilexetil
• Pharmaceutical form(s):
  • Tablet
  • Suspension for oral use
• Condition(s) / indication(s):
  • Diabetic retinopathy
  • Essential hypertension
  • Heart Failure
• Route(s) of administration:
  Oral use
• Contact for public enquiries:

  Takeda Global Research and Development Centre (Europe) Ltd

  E-mail: [e-mail]; Tel.: [phone]

• Decision type:
  RP: decision refers to a refusal on a proposed Paediatric Investigation Plan
• Decision date:
  20/02/2009

Decision

P/22/2009: European Medicines Agency decision of 23 February 2009 on the refusal of a Paediatric Investigation Plan and on the refusal of a waiver for candesartan cilexetil (Blopress and associated names), (EMEA-000023-P...

AdoptedReference Number: EMEA/96351/2009